Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. The company supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). The company supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The company supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Follow-Up Questions
¿Quién es el CEO de Hikma Pharmaceuticals PLC?
Mr. Riad Mishlawi es el Chief Executive Officer de Hikma Pharmaceuticals PLC, se unió a la empresa desde 2011.
¿Qué tal es el rendimiento del precio de la acción HKMPY?
El precio actual de HKMPY es de $47.47, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Hikma Pharmaceuticals PLC?
La capitalización bursátil actual de Hikma Pharmaceuticals PLC es $10.5B
¿Es Hikma Pharmaceuticals PLC una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 15 analistas han realizado calificaciones de análisis para Hikma Pharmaceuticals PLC, incluyendo 6 fuerte compra, 10 compra, 4 mantener, 0 venta, y 6 fuerte venta
